deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT00216164

Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase II Study of Rituximab and Gemcitabine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Hoosier Oncology Group LYM03-64

Sponsor: Eli Lilly and Company

Conditions Lymphoma, B-Cell
Interventions Gemcitabine Rituximab
Updated 5 times since 2017 Last updated: Apr 28, 2011 Started: Apr 30, 2005 Primary completion: Mar 31, 2007 Completion: Mar 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated due to lack of response at the first efficacy analysis

Other terminated trials from Eli Lilly and Company

See all terminations from Eli Lilly and Company

Listed as NCT00216164, this PHASE2 trial focuses on Lymphoma, B-Cell and remains terminated or withdrawn. Sponsored by Eli Lilly and Company, it has been updated 5 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 23 months · monthly snapshotTerminated

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
  • Hoosier Cancer Research Network
  • Walther Cancer Institute
Data source: Hoosier Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations